Sharon Manship, a Research Associate at the Centre for Health Services Studies, received the news this month like many in the endocrinology field—as a watershed moment. Polycystic Ovary Syndrome, the condition she has been studying intensively, is being officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) by European endocrinology specialists. Yet even Manship, who led groundbreaking research into the diagnosis experiences and support needs of those living with the condition across Kent, Surrey and Sussex, knows that a name alone cannot heal the systemic wounds this diagnosis has inflicted.
The renaming addresses a fundamental misconception that has plagued patients for decades: that PMOS affects only the ovaries and involves cysts. In reality, it is a full-body condition with cascading effects across multiple systems. That naming error has had real consequences—patients report severe delays in diagnosis, treatment and access to care, sometimes waiting years before receiving proper answers. The new name signals recognition that women's health has been historically underrecognized, underfunded and underresearched, a gap that is finally beginning to narrow.
But Manship and her fellow researcher, Kate Day, co-leaders of the Inclusive Women's Health Research Group at Kent, are clear-eyed about what the change does and does not accomplish. Working alongside an expert advisory group of four people with lived experience of PMOS, they examined the experiences of individuals with the condition and identified what truly needs to happen next. The answer is not merely semantic—it is structural.
The researchers found that genuine progress requires a multi-layered approach that extends far beyond what any name change can achieve. General practitioners and other healthcare professionals need substantially improved awareness, education and training to recognize PMOS in its varied presentations. Individuals living with the condition and their supporters need better access to information. But most critically, care provision and treatment pathways must become far more integrated, holistic and person-centered than they currently are, taking into account the broad manifestations of PMOS across metabolic, endocrine and psychological systems.
Mental health and wellbeing support emerged as particularly crucial in their research. The condition takes a significant psychological toll, yet patients often find themselves navigating fragmented support systems that treat PMOS as a single-issue diagnosis rather than the complex, systemic condition it is. Better frameworks for mental health care could dramatically improve quality of life and enable better disease management.
The recommendations from Manship and Day's research are now being circulated with hopes they will be adopted to improve practice in primary care and beyond. The timing is propitious—the name change has created an opening, a moment of collective attention. But the real work lies in what comes next: rebuilding how the NHS and healthcare systems understand, teach about and treat this condition at every level. The renaming is the flag planted. What matters now is the institutional will to climb the mountain.